Literature DB >> 21750048

IGFBP-2 enhances VEGF gene promoter activity and consequent promotion of angiogenesis by neuroblastoma cells.

Walid J Azar1, Sheena H X Azar, Sandra Higgins, Ji-Fan Hu, Andrew R Hoffman, Donald F Newgreen, George A Werther, Vincenzo C Russo.   

Abstract

IGF binding protein (IGFBP)-2 is one of the most significant genes in the signature of major aggressive cancers. Previously, we have shown that IGFBP-2 enhances proliferation and invasion of neuroblastoma cells, suggesting that IGFBP-2 activates a protumorigenic gene expression program in these cells. Gene expression profiling in human neuroblastoma SK-N-SHEP (SHEP)-BP-2 cells indicated that IGFBP-2 overexpression activated a gene expression program consistent with enhancement of tumorigenesis. Regulation was significant for genes involved in proliferation/survival, migration/adhesion, and angiogenesis, including the up-regulation of vascular endothelial growth factor (VEGF) mRNA (>2-fold). Specific transcriptional activation of the VEGF gene by IGFBP-2 overexpression was demonstrated via cotransfection of a VEGF promoter Luciferase construct in SHEP-BP-2. Cotransfection of VEGF promoter Luciferase construct with IGFBP-2 protein in wild-type SHEP cells indicated that transactivation of VEGF promoter only occurs in the presence of intracellular IGFBP-2. Cell fractionation and immunofluorescence in SHEP-BP-2 cells demonstrated nuclear localization of IGFBP-2. These findings suggest that transcriptional activation of VEGF promoter is likely to be mediated by nuclear IGFBP-2. The levels of secreted VEGF (up to 400 pg/10(6) cells) suggested that VEGF might elicit angiogenic activity. Hence, SHEP-BP-2 cells and control clones cultured in collagen sponge were xenografted onto chick embryo chorioallantoic membrane. Neomicrovascularization was observed by 72 h, solely in the SHEP-BP-2 cell xenografts. In conclusion, our data indicate that IGFBP-2 is an activator of aggressive behavior in cancer cells, involving nuclear entry and activation of a protumorigenic gene expression program, including transcriptional regulation of the VEGF gene and consequent proangiogenic activity of NB cell xenografts in vivo.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21750048     DOI: 10.1210/en.2011-1121

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  46 in total

1.  Is insulin-like growth factor binding protein 2 associated with metastasis in lung cancer?

Authors:  Qinghua Hu; Lingjin Huang; Xuyuan Kuang; Heng Zhang; Guoqiang Ling; Xuliang Chen; Kejiang Li; Zhenghao Deng; Jianhua Zhou
Journal:  Clin Exp Metastasis       Date:  2014-03-29       Impact factor: 5.150

2.  Estrogen Stimulation of Pleiotrophin Enhances Osteoblast Differentiation and Maintains Bone Mass in IGFBP-2 Null Mice.

Authors:  Gang Xi; Victoria E Demambro; Susan D'Costa; Shalier K Xia; Zach C Cox; Clifford J Rosen; David R Clemmons
Journal:  Endocrinology       Date:  2020-04-01       Impact factor: 4.736

3.  Peripheral Blood-Derived Mesenchymal Stromal Cells Promote Angiogenesis via Paracrine Stimulation of Vascular Endothelial Growth Factor Secretion in the Equine Model.

Authors:  Leen Bussche; Gerlinde R Van de Walle
Journal:  Stem Cells Transl Med       Date:  2014-10-13       Impact factor: 6.940

4.  CD44 expression in endothelial colony-forming cells regulates neurovascular trophic effect.

Authors:  Susumu Sakimoto; Valentina Marchetti; Edith Aguilar; Kelsey Lee; Yoshihiko Usui; Salome Murinello; Felicitas Bucher; Jennifer K Trombley; Regis Fallon; Ravenska Wagey; Carrie Peters; Elizabeth L Scheppke; Peter D Westenskow; Martin Friedlander
Journal:  JCI Insight       Date:  2017-01-26

5.  MDA-9/syntenin and IGFBP-2 promote angiogenesis in human melanoma.

Authors:  Swadesh K Das; Sujit K Bhutia; Belal Azab; Timothy P Kegelman; Leyla Peachy; Prasanna K Santhekadur; Santanu Dasgupta; Rupesh Dash; Paul Dent; Steven Grant; Luni Emdad; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher
Journal:  Cancer Res       Date:  2012-12-10       Impact factor: 12.701

6.  Glioma progression is mediated by an addiction to aberrant IGFBP2 expression and can be blocked using anti-IGFBP2 strategies.

Authors:  Lynette M Phillips; Xinhui Zhou; David E Cogdell; Corrine Yingxuan Chua; Anouk Huisinga; Kenneth R Hess; Gregory N Fuller; Wei Zhang
Journal:  J Pathol       Date:  2016-06-10       Impact factor: 7.996

7.  Protein Microarrays for Ocular Diseases.

Authors:  Guillermo Solís-Fernández; Ana Montero-Calle; Miren Alonso-Navarro; Miguel Ángel Fernandez-Torres; Victoria Eugenia Lledó; María Garranzo-Asensio; Rodrigo Barderas; Ana Guzman-Aranguez
Journal:  Methods Mol Biol       Date:  2021

8.  Insulin-like growth factor (IGF) binding protein 2 functions coordinately with receptor protein tyrosine phosphatase β and the IGF-I receptor to regulate IGF-I-stimulated signaling.

Authors:  Xinchun Shen; Gang Xi; Laura A Maile; Christine Wai; Clifford J Rosen; David R Clemmons
Journal:  Mol Cell Biol       Date:  2012-08-06       Impact factor: 4.272

Review 9.  Therapeutic mesenchymal stromal stem cells: Isolation, characterization and role in equine regenerative medicine and metabolic disorders.

Authors:  Mohamad Al Naem; Lynda Bourebaba; Katarzyna Kucharczyk; Michael Röcken; Krzysztof Marycz
Journal:  Stem Cell Rev Rep       Date:  2020-04       Impact factor: 5.739

Review 10.  IGF-binding protein 2 is a candidate target of therapeutic potential in cancer.

Authors:  Xiaofeng Yao; Shanshan Sun; Xuan Zhou; Wenyu Guo; Lun Zhang
Journal:  Tumour Biol       Date:  2015-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.